NASDAQ-Listed Cannabis Stocks vs OTC Cannabis Stocks: Which Is Better for Cannabis Investors?

The exchange where a cannabis stock trades has profound implications for liquidity, institutional access, valuation, and investor experience. The NASDAQ-vs-OTC divide is one of the most consequential structural features of cannabis investing and understanding it is essential for making informed decisions.

NASDAQ-listed cannabis stocks benefit from the full infrastructure of a major exchange. Institutional investors — mutual funds, pension funds, index providers — can freely trade NASDAQ securities without compliance concerns. This translates into deeper order books, tighter bid-ask spreads, and higher daily trading volumes. When you place a market order on a NASDAQ cannabis stock like Tilray, you can expect a fill within a penny of the quoted price. Real-time quotes are freely available through all major brokerages, and options chains are liquid for the most active names.

OTC cannabis stocks operate in a fundamentally different liquidity environment. Bid-ask spreads can range from a few cents for large MSOs like Curaleaf to five cents or more for smaller operators. Daily trading volume for even the largest MSOs is typically a fraction of what comparable NASDAQ-listed companies see. This means entering or exiting a substantial position takes more care — limit orders are essential, and large blocks may need to be worked over multiple days. Some brokers charge additional fees for OTC transactions, and real-time Level 2 OTC quotes may require a separate data subscription.

Settlement differences matter for active traders. NASDAQ securities settle on the standard T+1 cycle (trade date plus one business day). Most OTC cannabis stocks also settle T+1, but some foreign-domiciled OTC securities may have longer settlement periods or require DTC eligibility verification. Brokers occasionally impose their own additional settlement requirements on OTC cannabis positions, particularly for margin accounts where OTC stocks are typically not marginable.

The valuation implications of the NASDAQ-vs-OTC gap are significant and create what many analysts consider an inefficiency. Companies with similar revenue, growth rates, and operational quality often trade at materially different valuation multiples simply because of their exchange listing. NASDAQ-listed cannabis companies tend to command higher price-to-sales ratios because institutional capital can access them. OTC-traded MSOs frequently trade at 30-50% discounts on comparable metrics — a persistent valuation gap that could narrow dramatically if regulatory changes allow uplisting.

For investors, the practical decision often comes down to accessibility and conviction. NASDAQ cannabis stocks are easier to buy, trade, and monitor through any brokerage account. OTC cannabis stocks require a bit more effort but provide access to the US-plant-touching operators that many consider the best long-term opportunity in the sector. Sophisticated investors often hold both, using NASDAQ-listed names for liquidity and options trading while building core positions in OTC MSOs for their growth potential and reform-driven upside.